Page 8 - Small Molecules News Today

Lonza Group AG Key word Half Year Results Lonza Delivers 56% CER Sales Growth With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin 21Jul2023 0700 CETCEST Release of an ad hoc announcem

Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that it has partnered with Chemspace, the largest online catalogue of small molecules and biologics, to augment and streamline the Company’s small molecule microarray (SMM) service offering.

Lonza Group AG (OTCMKTS:LZAGY – Free Report) was the target of a significant drop in short interest in June. As of June 15th, there was short interest totalling 6,100 shares, a drop of 50.8% from the May 31st total of 12,400 shares. Based on an average daily trading volume, of 167,900 shares, the days-to-cover ratio […]

Lonza Group AG (OTCMKTS:LZAGY – Free Report) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among […]

Lonza Group AG (OTCMKTS:LZAGY – Free Report) was the target of a large drop in short interest in June. As of June 15th, there was short interest totalling 6,100 shares, a drop of 50.8% from the May 31st total of 12,400 shares. Based on an average daily trading volume, of 167,900 shares, the days-to-cover ratio […]

MyJournals.org - Science - [ASAP] Enhanced ASO-Mediated Gene Silencing with Lipophilic pH-Responsive Micelles (Bioconjugate Chemistry)

An atlas that catalogs gene activity and the levels of small molecules called metabolites in tumor samples offers a new way of identifying the deep mechanisms of cancer, according to researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 ...

- Following positive Phase 1/2 results in Vertex’s VX-880 program, Vertex and Lonza announce strategic manufacturing collaboration - - Dedicated large-scale facility will support commercial production of Vertex’s T1D cell therapy portfolio - - Approximately 300 new jobs anticipated at Lonza Portsmouth, New Hampshire Site -

Lonza Group AG (OTCMKTS:LZAGY – Get Rating) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $66.00 and last traded at $65.55, with a volume of 135655 shares. The stock had previously closed at $63.45. Wall Street Analysts Forecast Growth Several analysts recently issued reports on LZAGY […]